{
    "root": "9a09ccdd-e899-46c6-9a85-3ffbf3e824b1",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Gilenya",
    "value": "20250501",
    "ingredients": [
        {
            "name": "FINGOLIMOD HYDROCHLORIDE",
            "code": "G926EC510T",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63112"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_5291"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14077"
        },
        {
            "name": "MANNITOL",
            "code": "3OWL53L36A",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_29864"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32234"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00840"
        },
        {
            "name": "ADRABETADEX",
            "code": "8W6Q67R6NX",
            "drugbank_id": "https://go.drugbank.com/drugs/DB15146"
        }
    ],
    "indications": {
        "text": "gilenya indicated treatment relapsing forms multiple sclerosis ( multiple sclerosis ) , include clinically isolated syndrome , relapsing-remitting disease , active secondary progressive disease , patients 10 years age older .",
        "doid_entities": [
            {
                "text": "multiple sclerosis (DOID:2377)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_2377"
            },
            {
                "text": "syndrome (DOID:225)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_225"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            }
        ],
        "orphanet_entities": [
            {
                "disease": "relapsing-remitting disease",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_3408"
            }
        ]
    },
    "contraindications": {
        "text": "assessments required prior initiating gilenya . ( 2.1 ) recommended adults pediatric patients ( 10 years age older ) weighing 40 kg : 0.5 mg orally daily , without food . ( 2.2 , 2.3 ) recommended pediatric patients ( 10 years age ) weighing less equal 40 kg : 0.25 mg orally daily , without food . ( 2.2 , 2.3 ) first-dose monitoring ( including reinitiation discontinuation greater 14 days dose increases ) : observe patients bradycardia least 6 hours ; monitor pulse blood pressure hourly . electrocardiograms ( ecgs ) prior dosing end observation period required . ( 2.4 ) monitor resolution heart rate < 45 beats per minute ( bpm ) adults , < 55 bpm patients aged 12 years , < 60 bpm pediatric patients aged 10 12 years , atrioventricular ( av ) block , lowest postdose heart rate end observation period . ( 2.4 ) monitor symptomatic bradycardia ecg resolved . continue overnight intervention required ; repeat first-dose monitoring second dose . ( 2.4 ) observe patients overnight higher risk symptomatic bradycardia , heart block , prolonged qtc interval , taking drugs known risk torsades de pointes . ( 2.4 , 7.1 )",
        "doid_entities": [],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": "0.25 mg gilenya capsules supplied follows : hard gelatin capsules ivory opaque body cap , black radial imprint \u201c fty 0.25 mg \u201d cap black radial band capsule body carton 7 capsules containing 1 blister card 7 capsules per blister card ndc 0078-0965-89 0.5 mg gilenya capsules supplied follows : hard gelatin capsules white opaque body bright yellow cap imprinted \u201c fty 0.5 mg \u201d cap 2 radial bands imprinted capsule body yellow ink . bottle 30 capsules ndc 0078-0607-15",
    "adverseReactions": "gilenya contraindicated patients : last 6 months experienced myocardial infarction , unstable angina , stroke , transient ischemic attack ( tia ) , decompensated heart failure requiring hospitalization class iii/iv heart failure history presence mobitz type ii second-degree third-degree av block sick sinus syndrome , unless patient functioning pacemaker [ ( 5.1 ) ] baseline qtc interval \u2265 500 msec cardiac arrhythmias requiring anti-arrhythmic treatment class ia class iii anti-arrhythmic drugs hypersensitivity reaction fingolimod excipients gilenya . observed include rash , urticaria angioedema upon treatment initiation [ ( 5.14 ) ] .",
    "indications_original": "GILENYA is indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in patients 10 years of age and older.",
    "contraindications_original": "Assessments are required prior to initiating GILENYA. ( 2.1 ) Recommended dosage for adults and pediatric patients (10 years of age and older) weighing more than 40 kg: 0.5 mg orally once daily, with or without food. ( 2.2 , 2.3 ) Recommended dosage for pediatric patients (10 years of age and above) weighing less than or equal to 40 kg: 0.25 mg orally once daily, with or without food. ( 2.2 , 2.3 ) First-Dose Monitoring (including reinitiation after discontinuation greater than 14 days and dose increases): Observe all patients for bradycardia for at least 6 hours; monitor pulse and blood pressure hourly. Electrocardiograms (ECGs) prior to dosing and at end of observation period required. ( 2.4 ) Monitor until resolution if heart rate < 45 beats per minute (bpm) in adults, < 55 bpm in patients aged 12 years and above, or < 60 bpm in pediatric patients aged 10 to below 12 years, atrioventricular (AV) block, or if lowest postdose heart rate is at the end of the observation period. ( 2.4 ) Monitor symptomatic bradycardia with ECG until resolved. Continue overnight if intervention is required; repeat first-dose monitoring for second dose. ( 2.4 ) Observe patients overnight if at higher risk of symptomatic bradycardia, heart block, prolonged QTc interval, or if taking drugs with known risk of torsades de pointes. ( 2.4 , 7.1 )",
    "warningsAndPrecautions_original": "0.25 mg GILENYA capsules are supplied as follows:\n                        \n                        hard gelatin capsules with an ivory opaque body and cap, with black radial imprint \u201cFTY 0.25 mg\u201d on the cap and a black radial band on the capsule body\n                        Carton of 7 capsules containing 1 blister card of 7 capsules per blister card\n\t\t\t\t\t\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\n\t\t\t\t\t\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\n\t\t\t\t\t\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\t\t\t\t\t\t\tNDC 0078-0965-89\n                        \n                           0.5 mg GILENYA capsules are supplied as follows:\n                        \n                        hard gelatin capsules with a white opaque body and bright yellow cap imprinted with \u201cFTY 0.5 mg\u201d on the cap and 2 radial bands imprinted on the capsule body with yellow ink.\n                        Bottle of 30 capsules\u00a0\u00a0\u00a0\u00a0\u00a0\n\n\t\t\t\t\t\t\t\u00a0\u00a0\u00a0\u00a0\u00a0\n\t\t\t\t\t\t\tNDC 0078-0607-15",
    "adverseReactions_original": "GILENYA is contraindicated in patients who have:\n                  \n                     in the last 6 months experienced myocardial infarction, unstable angina, stroke, transient ischemic attack (TIA), decompensated heart failure requiring hospitalization or Class III/IV heart failure\n                     a history or presence of Mobitz Type II second-degree or third-degree AV block or sick sinus syndrome, unless patient has a functioning pacemaker [see Warnings and Precautions (5.1)]\n                     \n                     a baseline QTc interval \u2265 500 msec\n                     cardiac arrhythmias requiring anti-arrhythmic treatment with Class Ia or Class III anti-arrhythmic drugs\n                     had a hypersensitivity reaction to fingolimod or any of the excipients in GILENYA. Observed reactions include rash, urticaria and angioedema upon treatment initiation [see Warnings and Precautions (5.14)].",
    "drug": [
        {
            "name": "Gilenya",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_63112"
        }
    ]
}